Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS opens coverage analysis on MR angiography

This article was originally published in The Gray Sheet

Executive Summary

Medicare agency opens 30-day comment period on Oct. 7 for an internally-generated national coverage analysis of magnetic resonance angiography (MRA), a magnetic resonance imaging procedure for visualization of blood flow and diseased vessels. CMS recently lifted the national non-coverage status for MRI for blood flow, leaving decisions on MRA in the hands of local Medicare contractors. The agency seeks comments on the long- and short-term clinical outcomes of MRA for indications that remain non-covered in the Medicare population. Comments are due Nov. 6, and CMS plans to issue a final decision by July 6, 2010

You may also be interested in...

CMS merges coverage for magnetic resonance angiography and MRI

Medicare agency finalizes its decision memo June 3 on magnetic resonance angiography, a specific application of magnetic resonance imaging used for blood flow determination, consolidating provisions under a single national coverage determination. The decision eliminates certain non-coverage language for MRA, but leaves most coverage decisions to the discretion of local contractors. CMS opened the coverage determination last October (1"The Gray Sheet" Oct. 12, 2009)

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts